Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | Ruxolitinib in 2022 and beyond: the good, the suboptimal and the failure

Aaron Gerds • 10 Nov 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib
COMFORT-I COMFORT-II

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, gives a presentation on the current and future use of ruxolitinib in myeloproliferative neoplasms (MPNs) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Aaron Gerds

Using artificial intelligence to accelerate patient eligibility screening in clinical trials
1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Practical advice for community physicians managing patients with anemia and myelofibrosis
1:18
Practical advice for community physicians managing patients with anemia and myelofibrosis
Aaron Gerds • 23 Aug 2025
Mechanisms driving anemia in myelofibrosis and approaches under development for this complication
2:11
Mechanisms driving anemia in myelofibrosis and approaches under development for this complication
Aaron Gerds • 23 Aug 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Aaron Gerds • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Aaron Gerds • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Aaron Gerds • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Aaron Gerds • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals